Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Pyxis Oncology, Inc. (PYXS)
|
Add to portfolio |
|
|
|
| Price: |
$10.89
| | Metrics |
| OS: |
39.5
|
M
| |
-62
|
% ROE
|
| Market cap: |
$430
|
M
| |
-65
|
% ROIC
|
|
Net cash:
|
$25.9
|
M
| |
$0.66
|
per share
|
|
EV:
|
$405
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($91.9)
|
M
| |
|
|
| EPS |
($2.58)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 86.1 | 0.0 | 51.1 | 0.0 | 1.2 |
| Revenue growth | | 68.7% | | | -100.0% | |
| Cost of goods sold | 0.0 | 123.5 | 0.0 | 69.7 | 0.0 | 2.9 |
| Gross profit | 0.0 | -37.4 | 0.0 | -18.7 | 0.0 | -1.7 |
| Gross margin | | -43.4% | | -36.6% | | -135.2% |
| Research and development | 86.1 | | 51.1 | | 9.0 | |
| General and administrative | 37.4 | 37.4 | 18.7 | 18.7 | 3.8 | 1.7 |
| EBIT | -123.5 | -123.5 | -69.9 | -69.7 | -12.9 | -2.9 |
| EBIT margin | | -143.4% | | -136.6% | | -235.2% |
| Pre-tax income | -120.7 | 0.0 | -76.0 | 0.0 | -12.8 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | | 0.0% | |
| Net income | -120.7 | 0.0 | -76.0 | 0.0 | -12.8 | 0.0 |
| Net margin | | 0.0% | | 0.0% | | 0.0% |
| |
| Diluted EPS | ($3.65) | $0.00 | ($8.95) | $0.00 | ($12.45) | $0.00 |
| Shares outstanding (diluted) | 33.0 | 33,033.1 | 8.5 | 8,493.3 | 1.0 | 671.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|